Assessing the impact of the Inflation Reduction Act on drug development, plus ESMO data from Amgen, Chinese CAR T companies
By Jeff Cranmer, Executive Editor
September 13, 2022 12:14 AM UTC
Biopharma executives and investors are bracing for the impact of the newly passed Inflation Reduction Act. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin and Editor in Chief Simone Fishburn discuss pharma CEOs’ warnings that the law will reduce incentives for small molecule drug development, how biotech VCs may adjust deployment of their funds and how the government could implement the law.
Turning to readouts from the European Society of Medical Oncology (ESMO) Congress, Executive Director Lauren Martz explains why the latest data for Lumakras sotorasib from Amgen Inc. (NASDAQ:AMGN) could shake up the KRAS inhibitor race and how Chinese investigator-initiated trials are accelerating CAR T innovation.
This week’s podcast is sponsored by the BioCentury-BayHelix East-West Summit 2022, which takes place in the San Francisco Bay Area Nov. 14-16.For information on how to sponsor BioCentury This Week and/or The BioCentury Show, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.
